Delving into the Latest Updates on Donepezil Hydrochloride with Synapse

Overview

Basic Info

SummaryDonepezil, a minuscule molecular compound, functions as an acetylcholinesterase inhibitor, indicating that it hinders the degradation of acetylcholine, a neurotransmitter in the brain, and provides assistance in enhancing cognitive function. Patients in mild, moderate, and severe stages of Alzheimer's Disease receive this drug as a therapeutic agent. Initially authorized in November 1996 by Eisai, a pharmaceutical establishment situated in Japan, it has now expanded to a worldwide availability. Although Donepezil Hydrochloride does not hold the cure for Alzheimer's Disease, it does assist in controlling some of the symptoms associated with the disease, such as memory loss, confusion, and other cognitive impairments. As a crucial medication for those existing with Alzheimer's Disease, it can amplify their quality of life and curtail the progression of the disease.

Drug Type

Small molecule drug

Synonyms

ARIPEZIL, BNAG, Domepezil

+ [47]

Target

ACHE

Action

inhibitors

Mechanism

AChE inhibitors(Acetylcholinesterase inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Lewy Body DiseaseAlzheimer DiseaseDementia+ [1]

Inactive Indication

Advanced cancerAttention Deficit DisorderCadasil+ [13]

Originator Organization

Active Organization

+ [11]

Inactive Organization

Guangzhou Continent Biomedical Technology Co., Ltd.

Teikoku Pharma USA, Inc.

ICURE PHARM INC

+ [8]

License Organization

Inventage Lab, Inc.

ICURE PHARM INC

Lotus Pharmaceutical Co., Ltd.

+ [9]

Drug Highest PhaseApproved

First Approval Date

United States (25 Nov 1996),

Alzheimer Disease

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC24H30ClNO3

InChIKeyXWAIAVWHZJNZQQ-UHFFFAOYSA-N

CAS Registry120011-70-3

Due to their various pharmacological effects, several substituted sulphur heterocycles containing thiophene have recently attracted a great deal of attention. A novel 2,3-diaryl-2,3,5,6,7,8-hexahydro-4H-benzo[4,5]thieno[3,2-e][1,3]oxazin-4-one (9-14) was synthesised starting from cyclohexa[b]thiophene. Compounds 9 and 10 showed the greatest gene expression downregulation of BAX by 75.1% and 79.7%, and upregulation of Bcl-2 gene expression by 8.1 folds for each. It also decreased the level of AChE by 70.2 and 75%; respectively. Compounds 9 and 10 significantly increased Wnt3a levels by 5.8 and 6.6 folds, and β-Catenin levels by 10.1 and 10.5 folds, respectively, compared to donepezil. They significantly downregulated 5-GSK3β gene expression by 77.1%, and 78.7%, respectively. Even though all compounds exhibited potent inhibition of AChE, all synthesised compounds, except for compounds 5 and 11 demonstrated higher selectivity towards BChE (SI < 1). In-silico ADMET calculations as well as molecular docking have been performed for synthetic compounds.

31 Dec 2026·REDOX REPORT

Redox modulation contributes to the antidepressant-like and neuroprotective effects of 7-chloro-4-(phenylselanyl)quinoline in an Alzheimer’s disease model

Article

Author: Dos S Barboza, Victor ; Da C Rodrigues, Karline ; Lima, Ariana Silveira ; De A Vaucher, Rodrigo ; Savegnago, Lucielli ; Fidelis, Eduarda M ; Giongo, Janice L ; Luchese, Cristiane ; Alves, Diego ; De Oliveira, Renata L ; Quines, Caroline B ; Vogt, Ane G ; Pinz, Mikaela P ; Pinton, Simone ; Voss, Guilherme T

OBJECTIVES:

Alzheimer's disease (AD) is characterized by cognitive impairment and neuropsychiatric disturbances, including depression, both tightly linked to redox imbalance and neuroinflammatory activation. This study investigated whether the selenium-containing compound 7-chloro-4-(phenylselanyl)quinoline (4-PSQ) mitigates behavioral and biochemical alterations in a β-amyloid (Aβ)-induced mouse model of AD through modulation of redox-regulated pathways.

METHODS:

Male Swiss mice received intracerebroventricular Aβ (25-35) or saline (3 µL/site) and were treated orally for seven days with 4-PSQ (1 mg/kg), paroxetine (1 mg/kg), or donepezil (1 mg/kg). Depressive-like behavior and memory performance were assessed, followed by determination of plasma corticosterone, reactive species levels, lipid peroxidation, antioxidant enzyme activities, neuroinflammatory mediators, and acetylcholinesterase (AChE) activity in the hippocampus and prefrontal cortex of mice.

RESULTS:

4-PSQ significantly reversed Aβ-induced depressive behavior and memory impairment. The compound normalized plasma corticosterone levels, reduced reactive species and lipid peroxidation, and restored antioxidant enzyme activity. It also decreased the expression of inflammatory markers while regulating AChE activity, indicating concomitant modulation of redox, neuroimmune, and cholinergic pathways.

CONCLUSION:

By restoring redox homeostasis and attenuating neuroinflammatory responses, 4-PSQ effectively counteracted behavioral and biochemical disruptions associated with Aβ toxicity. These findings support 4-PSQ as a promising selenium-based therapeutic candidate targeting redox-driven features of AD, including comorbid depression and cognitive decline.

31 Dec 2026·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of donepezil-safinamide hybrids as dual AChE and MAO-B inhibitor for Alzheimer’s disease treatment

Article

Author: Yang, Chunyan ; Guo, Yan ; Cao, Zhongcheng ; Wang, Xiaoli ; Zhu, Jiang ; Li, Wei

Alzheimer's disease (AD) still lacks therapies that definitively halt its progression. Dual AChE/MAO-B inhibitors offer a promising strategy to address both symptoms and pathology. Here, we designed and synthesised a series of donepezil-safinamide hybrids. The optimised compound 28c was identified as a potent inhibitor of AChE (IC₅₀ = 1.70 μM) and MAO-B (IC₅₀ = 0.18 μM). Mechanistic studies indicated that 28c acts as a reversible mixed-type inhibitor of AChE and a competitive reversible inhibitor of MAO-B. Molecular docking and molecular dynamic simulations revealed that 28c could strongly and stably bind to MAO-B and AChE mainly through van der Waals interactions. Moreover, compound 28c demonstrated effective blood-brain barrier penetration, exhibited suitable stability in mouse plasma and brain homogenate, and showed a favourable safety profile both in vitro and in vivo. Furthermore, 28c could attenuate AD-related symptoms and exert hippocampal neuroprotection effect in vivo, highlighting its promise as an anti-AD candidate.

125

News (Medical) associated with Donepezil Hydrochloride

29 Apr 2026

·www.biospace.com

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at . Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening : 1-877-407-9039 or 1-201-689-8470 or Participants can use guest dial-in #s above and be answered by an operator, or click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time. The live audio webcast will be accessible here: A replay of the earnings call is available after the conference call has ended. Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Access ID: 13760339 Replay Webcast : About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form 10-K as filed with the SEC on March 31, 2026 and available at . These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts For further information: Investor Relations IR@alphacognition.com

Drug ApprovalFinancial Statement

27 Apr 2026

·www.businesswire.com

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum’s 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28, 2026 A live webcast of select presentations will be accessible in the Events & Presentations section of the Company’s investor relations website and archived for replay following the events. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization of ZUNVEYL, statement regarding the timing and potential outcomes of the Company’s ongoing clinical and preclinical studies, statements regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated operations of the Company. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our ongoing clinical trials and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company’s other filings with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Drug Approval

27 Apr 2026

·www.biospace.com

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences - April 27, 2026

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum’s 23 rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28, 2026 A live webcast of select presentations will be accessible in the Events & Presentations section of the Company’s investor relations website and archived for replay following the events. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization of ZUNVEYL, statement regarding the timing and potential outcomes of the Company’s ongoing clinical and preclinical studies, statements regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated operations of the Company. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our ongoing clinical trials and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company’s other filings with the SEC available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts For further information: Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

100 Deals associated with Donepezil Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00670	Donepezil Hydrochloride	N06DA02	DB00843

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dementia	United States	Corium LLC	11 Mar 2022
Lewy Body Disease	Japan	Eisai Co., Ltd.	19 Sep 2014
Alzheimer Disease	United States	Eisai, Inc.	25 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 3	United States	Pfizer Inc.	01 Sep 2008
Cognitive Dysfunction	Phase 3	United States	Eisai, Inc.	01 Sep 2008
Down Syndrome	Phase 3	United States	Pfizer Inc.	01 Sep 2008
Down Syndrome	Phase 3	United States	Eisai, Inc.	01 Sep 2008
Attention Deficit Disorder	Phase 3	United States	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	Argentina	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	Australia	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	Canada	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	Chile	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	France	Eisai Co., Ltd.	02 Jul 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05801380 (PHRR230220-0054116, Pubmed \| J Alzheimers Dis Rep)	Not Applicable	Alzheimer Disease	2	MemantineDonepezil + MemantineDonepezil	stlltwnusm(dikwpiwyyz) = glizvtyynu ptvcpzrdwp (cihdqpkwte ) View more	Negative	01 Mar 2026
NCT04117178 (MONANTI, CTgov)	Phase 4	Alzheimer Disease \| Dementia due to Parkinson's disease \| Lewy Body Disease	132	Measurement of serum level of anti-dementia drug (Standard of Care)	hramakmkbr(ccqmnsgrkw) = bfavzlcvyt xcjwbezipj (jcohomfgdm, 3.19) View more	-	10 Feb 2025
				Measurement of serum level of anti-dementia drug+Memantine+Donepezil (Intervention Arm)	hramakmkbr(ccqmnsgrkw) = faeiyyiygs xcjwbezipj (jcohomfgdm, 3.56) View more
NCT04730635 (MK-0000-413, CTgov)	Phase 1	Alzheimer Disease \| Mild cognitive disorder	44	Donepezil (Donepezil)	dmhrutbdaz(muqjbmomaw) = qpvqjlotua bnxkuelasc (cvwkdoztuc, 0.078) View more	-	28 Oct 2024
				Placebo (Placebo)	dmhrutbdaz(muqjbmomaw) = jzqtqysnsu bnxkuelasc (cvwkdoztuc, 0.091) View more
NCT04617782 (CTgov)	Phase 1	-	60	Donepezil (Treatment A 5 mg TDS)	vkckpeujzz(mkonjlnabb) = jcaiezpvfs auszgogkuc (locsfuhdav, 9.1) View more	-	19 Sep 2024
				Donepezil (Treatment B 10 mg TDS)	vkckpeujzz(mkonjlnabb) = chysbdakli auszgogkuc (locsfuhdav, 19.9) View more
NCT02487082 (CTgov)	Phase 2	Autism Spectrum Disorder	12	Placebo+Melatonin+Donepezil (Group A)	rfzslafeaw(yofppnvuxr) = fdqmjqagid mlrqfcvxgb (iutitxlgzs, awwwvgnvrw - ayyazgywio) View more	-	06 Jun 2024
				Placebo+Melatonin+Donepezil (Group B)	rfzslafeaw(yofppnvuxr) = etwtvdhuce mlrqfcvxgb (iutitxlgzs, yjbeivodjc - cltwebfmov) View more
NCT02345213 (Pubmed)	Phase 4	Lewy Body Disease	160	多奈哌齐	qgckczzpte(lgpufgzuze): difference = 1.4 (95% CI, 0.42 - 2.30), P-Value = 0.004 View more	Positive	04 Mar 2024
				安慰剂
NCT02822573 (Remember, CTgov)	Phase 3	Cognitive Dysfunction \| Breast Cancer \| Invasive Mammary Carcinoma	276	Donepezil 5 mg (Donepezil)	ptgzuizwaw(yrfbqswkre) = etzarqzpyl znyxlyvjrn (qrttcqwakg, xbbepubmvb - esnpqplibr) View more	-	13 Sep 2023
				Placebo (Placebo)	ptgzuizwaw(yrfbqswkre) = ehrncbuwci znyxlyvjrn (qrttcqwakg, siwjqdrojq - ezykifkbvm) View more
NCT04617782 (Pubmed \| J Alzheimers Dis)	Phase 1	-	60	10-mg/d Corplex™ donepezil transdermal delivery system	cmhtzpapuk(wmkiaaoklo) = oral donepezil was associated with higher incidence of gastrointestinal AEs (14.5% versus 53.6%) pkgpnslcuh (ofyfmeumfn ) View more	-	25 Oct 2022
				5-mg/d Corplex™ donepezil transdermal delivery system
NCT04617782 (ANA2022)	Phase 1	-	-	Once-weekly 5-mg/d donepezil TDS	nlruhywkmo(gqcbpqstlu) = combined skin irritation score of ≥ 3 reported in 51.7% and 54.5% of participants, 0.5 hours after 5- and 10-mg/d TDSs removal, respectively fvkgxbmpzj (nqritujyya )	-	14 Sep 2022
				Once-weekly 10-mg/d donepezil TDS
NCT04617782 (ANA2022)	Phase 1	-	60	Donepezil TDS 10mg/d	iwdebuyfbt(yeykgsnumv) = copzsufkrm zwumjpeqwb (ibziatjddb, 100.5 - 117.4) View more	Positive	14 Sep 2022
				Donepezil TDS 5mg/d	iwdebuyfbt(yeykgsnumv) = jzvnrqqcjg zwumjpeqwb (ibziatjddb, 97.6 - 113.6) View more